Canadian clinical stage biopharmaceutical company at Burnaby in British Columbia, founded in 1996 and listed on the American market, which works on medicines for neurological disorders. Built its research on the genetics of families with extreme pain and epilepsy phenotypes and develops ion channel modulators, with clinical programmes in epilepsy and major depressive disorder and earlier collaborations with Teva, Genentech and Neurocrine.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen